Working… Menu

Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02386007
Recruitment Status : Unknown
Verified October 2016 by Daewon Pharmaceutical Co., Ltd..
Recruitment status was:  Not yet recruiting
First Posted : March 11, 2015
Last Update Posted : October 12, 2016
Information provided by (Responsible Party):
Daewon Pharmaceutical Co., Ltd.

Brief Summary:
The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and safety of each dosage group in Korean patients with acute and chronic gastric inflammation.

Condition or disease Intervention/treatment Phase
Acute and Chronic Gastric Inflammation Patients Drug: DW-3101_150mg Drug: DW-3101_300mg Drug: DW-3101_600mg Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation
Estimated Primary Completion Date : July 2017

Arm Intervention/treatment
Experimental: DW-3101_150mg
150mg a day
Drug: DW-3101_150mg
Experimental: DW-3101_300mg
300mg a day
Drug: DW-3101_300mg
Experimental: DW-3101_600mg
600mg a day
Drug: DW-3101_600mg
Placebo Comparator: a tablet same as experimental agents in formation and shape
Drug: Placebo

Primary Outcome Measures :
  1. The change of gastric erosion score [ Time Frame: 14day±3 ]

    The erosion score is evaluated by gastroscopy. Erosion score The number of erosion

    1. 0
    2. 1~2
    3. 3~5
    4. More than 6 If patient's erosion score is decreased by 50% compared with erosion score before clinical dosing, we count it as effectiveness.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult males/females aged 20~75 years
  • Patients detected over 1 erosion who diagnosed as acute or chronic gastric inflammation by gastrscopy in 7days before administration of experimental agents
  • Subjects who voluntarily agree to participate in this clinical test with written consent

Exclusion Criteria:

  • Patients impossible gastroscopy
  • In case accompanied with gastric ulcer(scar excepted) or reflux esophagitis
  • Patients who had stomach or esophagus surgery to inhibit gastric acid secretion (tresis or appendicectomy surgery excluded)
  • Patients with malignant tumor on digestive organ
  • Patients with blood clot(cerebral thrombosis, myocardial infarction, septic thrombophlebitis) and who have antithrombotic agents (eg. warfarin)

Layout table for additonal information
Responsible Party: Daewon Pharmaceutical Co., Ltd. Identifier: NCT02386007     History of Changes
Other Study ID Numbers: DW 3101_201
First Posted: March 11, 2015    Key Record Dates
Last Update Posted: October 12, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases